1. Executive Summary (Confidence: High)

Timeline, the commercial brand of Amazentis SA, represents a paradigm shift in the longevity consumer market by bridging the gap between nutritional supplementation and pharmaceutical-grade clinical validation. Founded in 2007 as a spin-off from the École Polytechnique Fédérale de Lausanne (EPFL), the organization has spent nearly two decades elucidating the biological mechanisms of mitochondrial decay and its systemic impact on the human healthspan.^[1] The company's operations are anchored in a robust scientific foundation, characterized by over 15 years of rigorous research, more than 50 patents, and a clinical pipeline consisting of 25 human trials.^[1]

The central pillar of Timeline’s business is its proprietary compound, Mitopure, a highly pure form of Urolithin A that triggers mitophagy—a fundamental cellular recycling process that clears damaged mitochondria and replaces them with healthy ones.^[1] This mechanism addresses the primary hallamarks of aging, specifically mitochondrial dysfunction, which contributes to muscle weakening, immune exhaustion, and cognitive decline.^[2] Financially, the organization is backed by major industry incumbents, including Nestlé Health Science and L’Oréal, following a CHF 56 million Series D funding round in 2024.2 These partnerships signal a strategic move toward integrating longevity science into global food, beauty, and health sectors.^[3] As of early 2026, Timeline is positioning itself as the "world leader in clinically proven longevity," with expanding product lines in cellular nutrition and topical skin health.^[1]